Axion Biosystems is commercializing MEMS-based multielectrode array (MEA) technology, coupled with advanced signal processing circuitry, for in-vitro measurement of neural systems.
Redeon, acquired by Biovalve in 2001, was a microneedle company commercializing microfabrication-based approaches to transdermal drug delivery.